[Do we have adequate antimicrobials against methicillin-resistant Staphylococcus aureus?].
Muñoz Bellido
J L
JL
García-Rodríguez
J A
JA
D000900:Anti-Bacterial Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000502:physiology; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D015195:Drug Design; D024901:Drug Resistance, Multiple, Bacterial; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D006801:Humans; D016106:Methicillin Resistance; D046915:Penicillin-Binding Proteins; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D014481:United States / Q000453:epidemiology; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use; D018440:beta-Lactam Resistance; D047090:beta-Lactams / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015507:Drugs, Investigational; D046915:Penicillin-Binding Proteins; D047090:beta-Lactams; C487789:mecA protein, Staphylococcus aureus; D014640:Vancomycin